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Th seunm of a novel tumour marker, CA 242, defined by monoclonal antibody C 242,
was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA.
CA 242 is a carbohydrate cosely related, but not intical, to CA 19-9 and CA 50. The overl senstmty of
the CA 242 assy was 74%: S% in stage I, 83% in stage l-M and 78% in stage IV diseas. Tlh specificity
lated from 112 patients with benign diseas was 91%. CA 19-9 had a higher sensitivity of 83%, but the
specificity was only 81%. Wen com ring the markers by rer opaating aa sc analysis the
sensitivities were ahlost identical at specificity levels. The CA 242 was elvated in 7%, 15% and 7%
ofpatents with benign rc, biliary and liver disea respcvely. The cir nig figures for CA 19-9
were 19'!., 28% and 15% reslpcvely. The sensitivity of CA 242 was higher tan that ofCA 50 and CEA at
all specificity levels In cou_usion, tumour marker CA 242 so to be a useful tool for the
diagnois of pancreatic cancer, and is an alteaive to CA 19-9. The advantage ofCA 242 over CA 19-9 is its
higher specificity when the cut-off levels of the assays.
The CA 19-9 assay was first described by Del Villano et al.
(1983). It was soon shown that CA 19-9 is superior to CEA
in the diagnosis of pancreatic cancer (Jalanklo et al., 1984;
Haglund et al., 1986; Steinberg et al., 1986), and since then
CA 19-9 has been considered the standard marker for pan-
creatic cancer, with which other markers are compared. CA
19-9 is defined by monoclonal antibody 1116 NS 19-9 (19-9
antibody), reacting with sialosyl-fucosyl-lactotetraose, i.e.
sialylated Lewisa blood group antigen (Koprowski et al.,
1979; Magnani et al., 1982). CA 50, defined by monoclonal
antibody C 50 (C 50 antibody) (Lindholm et al., 1983), also
reacts with sialylated Lewis, and in addition with at least
one other carbohydrate, sialosyl-lactotetraose (Minsson et
al., 1985; Nilsson et al., 1985), although its affinity for this
carbohydrate is much weaker (Minsson et al., 1985; Nilsson
et al., 1985). In spite of the broader reactivity of the C 50
antibody, the CA 19-9 assay shows a similar (Harmenberg et
al., 1988) or even somewhat higher sensitivity for pancreatic
cancer than the CA 50 test (Haglund et al., 1987; Benini et
al., 1988).
CA 242 is a new tumour marker, based on monoclonal
antibody C 242 (C 242 antibody), obtained after immunisa-
tion of mice with a human colorectal adenocarcinoma cell
line, COLO 205, the same carcinoma cell line against which
the C 50 antibody was raised (Lindholm et al., 1985). The
structure of the antigenic determinant is not completely
defined, but it seems to be a sialylated carbohydrate structure
related to type I chain (Nilsson et al., 1992). It is related,
although not identicaL to the antigenic epitopes of tumour
markers CA 19-9 and CA 50.
In serum, the CA 242 epitope has been shown to be
coexpressed with CA 50 and with sialylated Lewis, i.e. CA
19-9, on the same macromolecular complex (Johansson et al.,
1991a, b). This has made it possible to set up a solid-phase
immunoassay, in which antibodie aginst sialylated Lewise
and the C 242 antibody are used as 'catcher' and 'detector'
antibodies respectively (Nilsson et al., 1988). This assay has
been shown to have a higher tumour specificity than the CA
50 test, which uses the C 50 antibody as both 'catcher' and
'detector' antibody (Johansson et al., 1991b). Previously we
have reported preliminary results of the CA 242 test in
patients with digestive tract malignancies (Kuusela et al.,
1991). This new marker has proved very promising and the
sensitivity and specificity for pancreatic cancer have been
similar to those of CA 19-9. In this study, the serum CA 242
levels were compared with those of CA 19-9 in 179 patients
with different stages of pancreatic cancer, using both the
recommended cut-off values of the tests and cut-off values
that adjust the speificities of the tests to similar levels. In
some of the patients, CA 242 was also compared with CA 50
and CEA.
Patems and mthods
Patients
Preoperative serum samples were obtained from 179 con-
secutive patients with verified pancreatic cancer. Patients
were classified according to the UICC TNM classification: 40
patients had stage I disease, 54 patients stage HI-III disease
and 85 patients stage IV disase. Most of the patients with
stage HI-Ill disease underwent a palliative operation. In
these operations, local lymph nodes were not always removed
adequately to allow differentiation between stages and III.
Therefore, patients with stage H and HI tumours, represent-
ing locally spread, non-resectable disease, were combined for
analysis. Histological type and differentiation grade were
determined when histological specimens were available.
For the control group, serum samples were collected from
112 patients with benign diseases that might cause symptoms
and signs that resemble those of pancreatic cancer. Benign
pancreatic disase was found in 42 patients: 22 patients with
acute pancreatitis and 20 with chronic pancreatitis. The
patients with benign biliary tract diseases (43 patients)
included 32 patients with stones in the common bile duct and
11 patents with gall blader stones, three ofwhom had acute
cholecystitis. All but four patients with common bile duct
stones showed various degrees of choletasis. Sera from 27
Patients with benign disases were tested: 17 patients
had acute viral hepatitis, four chronic hepatitis, three hepatic
cirrhosis, one acute alcoholic hepatitis, one primary biliary
cirrhosis and one benign adenoma.
Assays
The serum samples were frozen and stored at -20-C or
- 70'C before the assays. Serum CA 242 levels were
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measured by a dissociation-enhanced lanthanide fluoroim-
munoassay (DELFHA) (Wallac Oy, Turku, Finland) as previ-
ously described (Nilsson et al., 1988, 1992; Kuusela et al.,
1991). An upper limit of normal of 20 U ml-', corresponding
to the 99.4 percentile of healthy blood donors, has been
recommended for the assay (Nilsson et al., 1988). CA 19-9,
CEA (Abbot-Diagnostics, Chicago, IL, USA) and CA 50
(Pharmacia Diagnostics, Uppsala, Sweden) were quantitated
by solid-phase radioimmunoassays. Cut-off values of
37 Uml[', 5 ng ml-l and 17 Uml-', respectively, were used.
The inter-assay variations of the tests were below 5%, and
the intra-assay variations below 6%.
Statistical methods
For the comparison of vanrous tumour markers, cut-off
values representing the 90% and 95% specificity levels of
patients with relevant benign diseases were determined. The
correlation between the CA 242 and CA 19-9 concentrations
was calculated by linear regression using the logarithms of
the serum levels. Differences in mean values were calculated
using the Mann-Whitney U-test for non-paired samples.
Receiver operating characteristic (ROC) curves were con-
structed by calculating the true-positive fraction (sensitivities)
and false-positive fraction (specificities) of the CA 242 and
CA 19-9 assays at several cut-off points. ROC analysis is a
graphical method of comparing the sensitivity and specificity
of different diagnostic tests (Metz, 1978).
Results
CA 242 in pancreatic cancer
The serum level of CA 242 was higher than 20 U ml1 in 133
out of 179 patients with pancreatic cancer (74%) (Figure 1,
Table I). The median value was 141 Uml-', mean
25,822UmlP' and range 0-2,166,00OOUml[. Of these
patients, 94 (53%) had a level higher than 111 U ml'l, which
was the highest value found in patients with benign diseases.
CA 242 was elevated in 22 out of 40 patients with stage I
disease (55%), in 45 out of 54 patients with stage II-III
disease (83%) and in 66 out of 85 patients with stage IV
disease (78%). The CA 242 level was significantly higher in
stage H-Ill (P= 0.02) and in stage IV patients (P=0.002)
than in patients with stage I diseas. The difference between
stage II-IH and stage IV patients was not significant
(P= 0.24). The CA 242 level in patients with pancreatic
cancer was significantly higher than in patients with benign
diseases (P=0.0001). This was also true when comparing
different stages of pancreatic cancer with benign diseases
(P = 0.0001).
CA 242 in benign diseases
The serum concentration of CA 242 was increased above the
cut-off level of 20 U ml-' in 10 out of 112 patients (9%) with
benign diseases of the pancreas, biliary tract and liver (Figure
1, Table I). The median value was 6 U ml-', the mean value
IOU ml-l and the highest value 111 U ml-'. Five out of 43
patients with benign biliary diseases (15%) had an increased
serum concentration (median 6Uml-1, mean 12UmlV',
range 0- 11 U ml-'). All five patients had common bile duct
stones with cholestasis. Of 42 patients with beign pancreatic
diseases, elevated CA 242 levels were seen in three patients
with chronic pancreatitis, but in none with acute pancreatitis
(7%; median 6 U ml-', mean 10 U ml[', range 0-46 U ml-').
Of 27 patients with benign liver diseases, two patients with
acute viral hepatitis had a slightly elevated CA 242 level (7%;
median 4 U mlV ", mean 8 U ml' -, range 0-40 U ml ').
CA 19-9 in pancreatic cancer
The serum CA 19-9 concentration was higher than 37 U ml-'
in 148 out of 179 patients with pancreatic cancer (82.7%)
(Figure 1, Table I). The median value was 560 U ml-', mean
22,402Uml-' and range 0-1,858,900Unml1. Of these
patients 63 (35%) had a level higher than 1,400 U m[-,
which was the highest value of the benign group. CA 19-9
was elevated in 27 out of 40 patients with stage I disease
(68%), in 49 out of 54 patients with stage II-Ill disease
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Fugwe I Serum CA 242 concentrations in patients with pan-
creatic cancer, and with benign pancreatic, biliary and liver
diseases. The cut-off value for the CA 242 test is marked with a
dashed line.
Table I Comparison ofCA 242andCA 19-9 inpatientswith pancreaticcancerandpatientswithbenign pancreatic, biliaryandliver
diseases, using the recommended cut-off levels and cut-off levels representing the 90% and 95% specificity levels
CA 242 CA 19-9 CA 242 CA 19-9 CA 242 CA 19-9
>20Cmti >37Umim >19JSUmlC >60LmtC >27Cm1i >111JUmC
No. (%) (%) (%) (%) (%) (%)
Pancreatic cancer 179 74 83 75 78 70 72
Stage I 40 55 68 58 65 50 60
Stage Il-Ill 54 83 91 83 83 78 76
Stage IV 85 78 85 78 78 74 75
Benign diseases 112 9 19 10 10 5 5
Benign pancreatic diseases 42 7 12 10 5 5 2
Benign biliary diseases 43 15 28 14 19 5 12
Benign liver diseases 27 7 15 7 4 7 0
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(91°%) and in 72 out of 85 patients with stage IV disease
(85%). The CA 19-9 level was significntly higher in stage
II-III (P = 0.007) and in stage IV patients (P= 0.001) than
in patients with stage I disease. The difference between stage
H-HI and stage IV patients was non-significnt (P = 0.33).
The CA 19-9 lvel in all stages of pancreatic cancer was
significntly higher than in patients with benign diseases
(P = 0.0001).
CA 19-9 in benign diseases
The serum concentration ofCA 19-9 was increased above the
cut-off level of 37Uml-' in 21 out of 112 patients with
benig diseases of the pancreas, biliary tract and liver (19%;
median 12 Uml-', mean 41 U ml-', range 0-1,400 Uml[')
(Figure 1, Table I). The CA 19-9 level was elevated in 12 out
of 43 patients with benign biliary dis (28%; median
16 Uml-', mean 77 U ml-l, range 0-1,400 Uml-'). Nime of
these patents had common bile duct stones with various
degree of extrahepatic cholestasis, one patient had acute
cholcystitis and two patients had gall bladder stones without
chokcystitis. In benign pancreatic diseases CA 19-9 was
elevated in three patients with chronic and two patients with
acute pancreatitis (12%; median 10 Uml-', mean 20 Uml-',
range 0-185 U ml-'). Four patients with benign liver disease
(15%) had an elevated CA 19-9 serum level: two with viral
hepatitis, one with cirrhosis, and one with acute alcoholic
hepatitis.
Comparison ofCA 242 and CA 19-9
There was a high correlation between the CA 242 and CA
19-9 levels in serm (r2 = 0.732). The sensitivity of the CA
19-9 test for pancreatic cancer was higher than that of the
CA 242 test in all stage groups, but the specificity was ckarly
lower. When comparing the two markers by ROC curve
analysis, the curves were nearly identical (Figure 2). At the
90% specificity leveL the sensitivity of CA 242 was 75% and
that of CA 19-9 78%. The corrsponding cut-off levels were
19.5 Uml-' and 60 U ml-' r vely. At the 95% specifi-
city leveL the sensitivities for CA 242 and CA 19-9 were 70%
and 72%, respectively, and the cut-off values were 27 Uml-'
and II Uml-' respectvely (Table I).
Using the recomnd cut-off values, two patients with
pancreatic cancer had an elevated CA 242 level but a normal
CA 19-9 level, while the opposite was true in 17 patients. If
elevation of either CA 242 or CA 19-9 was considered a
positive result, the overall sensitivity of the combination of
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the markers was 84%. If both markers were required to be
elevrated for a positive test result, the overall senstivity was
73%. The correponding specificities were 80% and 93%
resectively.
Eight out of ten patients with benign diseases with elevated
CA 242 level also had an ekevated CA 19-9 klvel. The highest
serum levels ofCA 19-9 were 1,400, 410 and 365 Uml-', and
the corresponding CA 242 levels 58, 3 and 26 U ml-' respec-
tively. The highet CA 242 levels were 111, 58 and 46Uml-'
and the corresponding CA 19-9 levels 126, 1,400 and
46Uml-'. The assay parameters for the CA 242 and CA
19-9 assays, and for the combinations of the tests, are sum-
marised in Table II.
Comparison ofserwn CA 242, CA 19-9 andhistologicalgrade
The serum level of CA 242 was correlated with the histo-
logical differtiation grade in 111 patients: 78 with well-or
moderately differentiated adenocarcinoma and 33 with
poorly differentiated or anaplastic carcinoma. When analys-
ing all patients no difference was seen between the groups.
When patients were divided according to stage, there was -a
significnt difference in stage IV. Patients with well- or
moderately differentiated tumours had a higher serum CA
242 level than patients with poorly differetiated tumours
(P= 0.04). A difference was also seen for CA 19-9, but it was
not signnt. In stage I and stage H-HI, patients with
poorly differentiated carcinomas had slightly higher serum
CA 242 and CA 19-9 levels than patients with well- or
moderately differentiated carcinomas, but the number of
patients with poorly differentiated tumours was very small
and the difference was not significant.
Compaison ofCA 242 with CA 50 and CEA
The CA 50 level was availabk in 72 patients with pancreatic
cancer and in 67 patients with benign diseases. The CEA
concentration was available in 156 and 69 patients respec-
tively. Using inear regression there was a high correlation
between CA 242 and CA 50 (r2 = 0.846), but no correlation
between CA 242 and CEA (r2 = 0.314). When comparing CA
242 with CA 50 and CEA by ROC curve analysis, CA 242
had a higher sensitivity than CA 50 at every specificity level,
and a higher sensitivity than CEA at all spificity levels
higher than 70% (Figures 3 and 4).
If elevation of both CA 242 (>2OUml-') and CEA
(>5 ngml-') was considerd a positive test result, only 33%
showed a positive test. Ifelevation ofeither CA 242 or CEA
was considered a positive result, the sensitivity of the com-
bination of the markers was 85%. The corresponding specifi-
city was 81X%. At this speificity level the sensitivity of the
CA 242 test alone was 78%.
Comprison ofCA 242 and CA 19-9 according to serwn
biirubin kvel
Patients with benign disease and an elevated serum bilirubin
level (>20pmol 1-) had signifintly higher mean serum CA
19-9 concentration than patients with a normal bilirubin level
(P<0.05). No difference was seen for CA 242 (P= 0.99). In
Table I Assay parameters for the CA 242 and the CA 19-9 assays in
pancreatic caner
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Fwe 2 ROC curves for CA 242 ( )and CA 19-9 (---) in
pancreatic cancer. T'he true-positive fraction was calculated from
179 patients with pancreatic cancer, and the false-positive frac-
tion from 112 patients with benign pancreatic, biliary and liver
dis.
Away parameter CA 242 (%) CA 19-9 (%)
Sensitivity 74 83
Specificity 91 81
Positive predictive vahlu 93 88
Negtive predictive valu 70 75
Cut-off vahls: CA242, 20Uml-1; CA 19-9, 37Uml-'.
Sensitivity=TP/(TP+FEN); specifity=TN/(TN+FP); positive
redi ve value = TP/(TP+ FP); neative predictive vahle =TN/
(TN + FN);. TP, true positive; FN, false negtive; TN, true neative;
FP, false positive.
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FuWe 3 ROC curves for CA 242( ) and CA 50 (---)in
pancreatic cancer. The true-positive fraction was cakulated from
72 patients with pancreatic cancer, and the false-positive fraction
from 67 patients with benign pancreatic, biliary and liver
discase.
cancer patints, the difference between patients with elevated
versus normal bilirbin level was not significant in any stage
group. CA 19-9: stage I, P=0.78; stage II-HII, P=0.13;
stage IV, P=0.10. CA 242: stage I, P=0.47; stage II-Ill,
P=0.45; stage IV, P=0.39.
Using linear regression there was no correlation between
the serum levels of tumour markers CA 242/CA 19-9 and
serum bilirubin (r2=0.041/0.11) and alkalin phosphatase
(r2 = 0.045/0.07).
During the 10 years that CA 19-9 has been available for
clinical use (Del Villano et al., 1983), it has gained a position
as reference marker for pancreatic cancer, with which new
markers are compared. Only some years after the presenta-
tion of CA 19-9, another tumour marker CA 50, recognising
the same antigenic determinant, the sialylated Lewis antigen,
was described (Lindholm et al., 1983). In serum, both
markers are associated with a high molkcular weight carbo-
hydrate-rich mucin fraction (Lindholm et al., 1983; Magnani
et al., 1983). Johansson et al. (1991a, b) have demonstrated
coexpression ofCA 50 and sialylated Lewis, i.e. CA 19-9, on
the same macromolcular complex, which they call CanAg.
This macromolecule also expresses other antigens, including
CA 242, a carbohydrate different from CA 19-9 and CA 50
(Nilsson et al., 1992).
CA 242 is defined by monoclonal antibody C 242,
obtained by the same immunisation procedure as the C 50
antibody (Lindholm et al., 1985). Different combinations of
antibodies were studied in order to achieve optimal sensitivity
and specificity for the macromolecule expressing these
antigens (Johansson et al., 1991b). An assay using an
antibody against sialylated Lewis as catcher and the C 242
antibody as detector antibody showed better specificity for
cancer than the CA 50 assay, which uses C 50 as both
catcher and detector antibody. This assay has been intro-
duced as the CA 242 marker test.
Preliminary results on the serum expression of CA 242 in
pancreatic cancer were described in 1991 by Kuusela et al.
Later other small series including 24-68 patients were
reported (Nilsson et al., 1992; Pasanen et al., 1992; Banfi et
al., 1993; R6thlin et al., 1993). The results were promising
and CA 242 has shown sensitivities and specficities similar to
those of CA 19-9 and CA 50. For this study we colklcte a
large series of 179 patients with pancreatic cancer, enabling
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F-gwe 4 ROC curves for CA 242 ( ) and CEA (---) in
pancreatic cancr. The true-positive fraction was calulated from
156 patients with pancreatic cancr, and the fale-positive frac-
tion from 69 patients with benign pancreatic, biliary and liver
tiseas
division of patients in stage groups according to the UICC
TNM clasification.
Our study confirms previous obsations that the assay
parameters of CA 242 are similar to those ofCA 19-9 in the
primary diagnosis of pancreatic cancer (Kuusela et al., 1991;
Banfi et al., 1993; R6thlin et al., 1993). The highest serum
levels of CA 242 and CA 19-9 were found in patients with
unresectable dies, which can be diagnosed by other
clinical, radiological and laboratory investigations rather
easily. In stage I disease, in which surgical treatment with
curative intent is possible, more than half of the patients had
ekevated CA 242 and CA 19-9 levels at the 90% seificity
level (58% and 65% respectively). If five patients with resec-
table stage H-HI tumours were included, 60% of patients
with resectable disease had an elevated CA 242 leveL and
67% an elevated CA 19-9 klvel.
There was a high correlation between the serum levels of
CA 242 and CA 19-9. Using ROC curve analysis the results
were nearly identical. Usually both markers were elevated in
the same patients, and in most patients with either marker
elevated and the other normal the difference in serum con-
centration was small. However, a small number of patients
had a high CA 242 serm concentration but only slightly
ekevated CA 19-9 or vie versa. These patients show that, in
spite of the similarity of the markers, there are in some
patients ckar differences in the expression of the antigens.
The reason for this is still not known.
When comparing the serm CA 242 klvel with the histo-
logical differentiation grade, stage IV patients with well- to
moderately differentiated carcinomas had significntly higher
CA 242 levels than patients with poorly differentiated car-
cinomas. This is in concordance with immunohistochemical
findings showing ckarly stronger expression of CA 242 in
well- to moderately differentiated tumours than in poorly
differentiated or anaplastic carcinomas (Haglund et al.,
1989). In stage I and H-HI patiets, poorly differentiated
tumours semed to be associated with slightly higher CA 242
levels than well- to moderately differentiated tumours. How-
ever, the number of patients with poorly differentiated
tumours in these stage groups was too small for definite
conclusions to be drawn.
Because of the high correlation between the test results
there was no advantage in combining CA 242 with CA 19-9
or CA 50. No correlation was sn between CA 242 and
CEA. A combination of CA 242 and CEA increased the
sensitivity by 7% at the 81% specificity klwl. Combination
of CA 19-9 and CEA increased the sensitivity by 4% com-
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pared with CA 19-9 alone. However, the clnical utility of
combining the tests is limited by the fact that the majority of
patients with elevated CEA and normal CA 242 or CA 19-9
had disseminated disease.
The highest fiequency of false-positive CA 19-9 levels has
been described in patients with extrahepatic jaundice
(Jalanko et al., 1984; Haglund et al., 1986; Steinberg et al.,
1986), and this was confirmed in our study. In this patent
group there was a difference between CA 19-9 and CA 242 in
favour of CA 242. Although elevated CA 242 levels were
found in some patints with common bile duct stones, the
frequency of elevated levels was lower, and the increase in
the serum concentration smaller than that of CA 19-9. When
analysing all patients with benign di , sigfntly
higher CA 19-9 levels were seen in jaundiced compared with
non-jaundiced patients, whereas no signiant difference was
seen for CA 242. The highest CA 19-9 serum concentrations
have been reported in patients with cholangitis (Albert et al.,
1988). In the present study, one patient with a CA 19-9 value
of 1,400 U ml ' had cholangitis. The corresponding CA 242
serum level was only 58 Uml-'. A larger series of patients
with cholangitis should be colected to further evaluate the
potential advantage of CA 242 over CA 19-9.
At the time of diagnosis, most patients with pancreatic
cancer show extrahepatic cholstasis with elevated serum
levels ofbilirubin and alkaline phosphatase. It seems obvious
that cholstasis contributes to eklvated marker levels in these
patients. In stage H-IV cancer patients, the mean values of
CA 19-9 and CA 242 appeared higher in jaundiced than in
non-jaundiced patients, although the differences were not
significnt. The P-vahles were lower for CA 19-9 than for
CA 242, supporting the findings seen in benign diseases. In
clinical practice, biliary decompresson has been found to
reduce the CA 242 and CA 19-9 levels to a variable degree
(C. Haglund et al., unpublished data). In spite of the higher
frequency of elevated marker levels in cancer patients with
cholstasis, there was no clear-cut correlation between the
serum levels of these two tumour markers in malignant or
benign diseases and the serum levels of bilirubin or alkaline
phosphatase. This may be explaied by the fact that a
minority of tumours do not express CA 242 or CA 19-9
(Haglund et al., 1989), and these patients have a normal
serum lvel even though they might be jaundied. On the
other hand, some patients have high tumour production and
strong serum expression of these antigens without obstruc-
tion of the common bile duct.
Preperatively, chronic pancreatitis can sometimes be very
difficult to differentiate from pancreatic cancer. In these
patients tumour markers might be helpful. Only three out of
20 patients with chronic pancreatitis had an elvated CA 242
level, but none of the patients with acute pancreatitis did.
The highest value found in patients with chronic pancreatitis
was 46 U ml-'. Hence, in this series a clearly eklvated tumour
marker lvel strongly indicated malignant disease. On the
other hand, half of the patients with stage I tumours and
31a% of patients with stage HI-Il tumours had a CA 242
serum level below 46Uml['. Similarly, 55% and 28% of
stage I and stage II-Ill patients, respvely, had a CA 19-9
level below 185 U ml-', which was the highest value found in
patients with pancreatitis.
Benign liver disease is frequently associated with elevated
CA 19-9, CA 50 and CEA kevels (Jalanko et al., 1984; Chan
et al., 1985; Steinberg et al., 1986). In this study 4 of 27
patients had a slightly eklvated CA 19-9 level, but only two
patients with acute viral hepatitis had an elevated CA 242
level. Our material included only a few patients with chronic
liver diseas, and further studies are needed to evaluate the
possible influence of chronic liver failure on the CA 242
level.
In conclusion, CA 19-9 has in many studies and in clnical
practice been shown to be a useful complement to other
diagnostic methods in symptomatic patients with pancreatic
cancer. An elevated tumour marker level may kad to an
intensifed search for pancreatic cancer. In this study we
report the results on a novel tumour marker, CA 242, which
are similar to those of CA 19-9 in the primary diagnosis of
pancreatic cancer. In clinical work, the higher specificity
when using the recommended cut-off levels of the tests is a
clear advantage of CA 242 compared with CA 19-9. Studies
comparing CA 242 and CA 19-9 in follow-up and as prog-
nostic markers are ongoing, and will help to decide whether
CA 242 might replace CA 19-9 as the standard marker for
pancreatic cancer. CA 242 also seems to be very promising in
the diagnosis of colorectal cancer (Kuusela et al., 1991; Nils-
son et al., 1992). If CA 242 becomes a routine marker for
colorectal cancer, it would seem to be convenient to use the
same marker in patients with pancreatic cancer.
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